779329-61-2

Usage

Chemical structure

1-bromo-4-(ethylsulfonyl)-2-fluorobenzene consists of a benzene ring with a bromine atom at the 1 position, a fluorine atom at the 2 position, and an ethylsulfonyl group at the 4 position.

Functional groups

The compound contains a bromine atom, a fluorine atom, and an ethylsulfonyl group.

Synthesis

It is used in organic synthesis and pharmaceutical research as a building block for more complex molecules.

Applications

It can be used as a starting material for the synthesis of various pharmaceuticals and agrochemicals.

Pharmacological properties

The presence of the ethylsulfonyl group makes 1-bromo-4-(ethylsulfonyl)-2-fluorobenzene a sulfonamide, which can provide various pharmacological properties such as antimicrobial and antidiabetic activities.

Biological activity

The fluorine atom in the compound can enhance its biological activity and serve as a useful handle for further manipulations in drug design and discovery.

Upstream product

• 1620220-66-7 C₆H₆BrFN₂O₂S 
• 75-03-6 ethyl iodide 
• 351003-51-5 4-bromo-3-fluorobenzene-1-sulfonyl chloride 

Downstream Products

• 1614246-66-0 2-(6-chloro-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-68-2 2-(4'-(ethylsulfonyl)-2',6-dimethoxy-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-14-8 5-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-2-carbonitrile 
• 1614246-88-6 4'-(ethylsulfonyl)-2'-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,1'-biphenyl]-2-ol 
• 1614246-15-9 5-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4'-(ethylsulfonyl)-2'-methoxy-[1,1'-biphenyl]-2-ol 
• 1614246-36-4 2-(4-(ethylsulfonyl)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614245-70-3 4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7-ethyl-7H-imidazo[4,5-c]pyridazine 
• 1614245-88-3 7-cyclopropyl-4-(4'-(ethylsulfonyl)-2',6-difluoro-[1,1'-biphenyl]-3-yl)-7H-imidazo[4,5-c]pyridazine 
• 1614246-01-3 4-[4'-(ethylsulfonyl)-2',6-difluorobiphenyl-3-yl]-7-(propan-2-yl)-7H-imidazol[4,5-c]pyridazine 
• 1614246-10-4 7-cyclopentyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[1,1'-biphenyl]-3-yl)-7H-imidazo[4,5-c]pyridazine 
• 1614246-76-2 2-(4'-(ethylsulfonyl)-2'-fluoro-6-methoxy[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614246-11-5 7-ethyl-4-(4'-(ethylsulfonyl)-2'-fluoro-6-methoxy-[1,1'-biphenyl]-3-yl)-7H-imidazo[4,5-c]pyridazine 
• 1403329-89-4 1-bromo-2-ethoxy-4-(ethylsulfonyl)benzene 
• 1614246-34-2 1-bromo-4-(ethylsulfonyl)-2-methoxybenzene 

Relevant academic research and scientific papers

Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865)

The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABAA ligand-gated ion channel are described. From a set of initial hits multiple subseries were designed and evaluated based on binding affinity and functional activity. As designing in the desired level of functional selectivity proved difficult, a probability-based assessment was performed to focus the project's efforts on a single subseries that had the greatest odds of delivering the target profile. These efforts ultimately led to the identification of two precandidates from this subseries, which were advanced to preclinical safety studies and subsequently to the identification of the clinical candidate PF-06372865.

Chemical Compounds

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

NOVEL COMPOUNDS

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation